Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
15 Apr 24
8-K
Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
15 Apr 24
8-K
Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement
11 Apr 24
8-K
Unregistered Sales of Equity Securities
10 Apr 24
8-K
Novo Integrated Sciences Provides Update on Certain Current Actions and Events
26 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Regulation FD Disclosure
21 Feb 24
8-K
Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note
20 Feb 24
8-K
Novo Integrated Sciences Appoints New President
16 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Feb 24
10-Q
2024 Q1
Quarterly report
22 Jan 24
8-K
Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results
22 Jan 24
NT 10-Q
Notice of late quarterly filing
16 Jan 24
8-K
Regulation FD Disclosure
19 Dec 23
10-K
2023 FY
Annual report
14 Dec 23
8-K
Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results
14 Dec 23
8-K
Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India
5 Dec 23
8-K
Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval
4 Dec 23
NT 10-K
Notice of late annual filing
29 Nov 23
8-K
Entry into a Material Definitive Agreement
27 Nov 23
8-K
Regulation FD Disclosure
24 Nov 23
8-K
Novo Integrated Sciences Announces Reverse Stock Split
6 Nov 23
8-K
Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days
6 Nov 23
8-K
Novo Integrated Sciences Announces Issuance of Underlying One Billion Dollar Gold Backed Bond
3 Nov 23
8-K
Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program
24 Oct 23
8-K
Regulation FD Disclosure
13 Oct 23
8-K
Novo Integrated Sciences Provides Update on Certain Current Events
6 Oct 23
8-K
2023 Virtual Annual Meeting of Stockholders
2 Oct 23
8-K
Novo Integrated Sciences Signs Master Collateral Transfer Agreement
28 Sep 23
DEFA14A
Additional proxy soliciting materials
27 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Sep 23
8-K
Entry into a Material Definitive Agreement
22 Sep 23
DEFA14A
Additional proxy soliciting materials
21 Sep 23
8-K
Novo Integrated Sciences Provides Update on Certain Current Actions and Events
21 Sep 23
8-K
Entry into a Material Definitive Agreement
18 Sep 23
8-K
Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health
13 Sep 23
8-K
Novo Integrated Sciences Provides Update on Potential Share Repurchase Program
8 Sep 23
8-K
Novo Integrated Sciences Receives Underwriter Clearance Notice for $70,000,000 Coupon
31 Aug 23
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
30 Aug 23
Latest ownership filings
SC 13G/A
Hudson Bay Capital Management LP
6 Feb 24
4
Christopher Mehlin David
2 Jun 23
SC 13G/A
Hudson Bay Capital Management LP
10 Feb 23
4
Sarfaraz Ali
10 Aug 22
3
Sarfaraz Ali
10 Aug 22
4
Robert Letterio Oliva
21 Apr 22
4
Robert Letterio Oliva
24 Feb 22
4
Alex Flesias
24 Feb 22
4
Michael Ross Pope
24 Feb 22
SC 13G
Hudson Bay Capital Management LP
8 Feb 22
SC 13G
Hudson Bay Capital Management LP
8 Feb 22
3
Sterling M. Jimenez
28 Apr 21
4
Robert Letterio Oliva
23 Apr 21
3
THOMAS EDWARD BRAY
2 Mar 21
4
Robert Letterio Oliva
23 Feb 21
3/A
Robert Letterio Oliva
23 Feb 21
3
Michael Ross Pope
19 Feb 21
3
Michael Joseph Gaynor
19 Feb 21
3
Alex Flesias
19 Feb 21
3
Robert Letterio Oliva
19 Feb 21
3
Pierre Joseph Dalcourt
19 Feb 21
3
Christopher Mehlin David
19 Feb 21
3
Robert Mattacchione
19 Feb 21